Neprofitna organizacija Public Health and Medical Professionals for Transparency toži ameriški FDA!





Člani organizacije Public Health and Medical Professionals for Transparency

so med drugimi tudi:


a. Aaron Kheriaty, MD Professor of Psychiatry,

UCI School of Medicine Director, Medical Ethics Program, UCI Health

b. Harvey Risch, MD, PhD Professor of Epidemiology

Yale School of Public Health

c. Peter A. McCullough, MD, MPH, FACP, FACC, FCCP, FAHA, FNKF, FNLA, FCRSA

d. Carole H Browner, PhD, MPH Distinguished Research Professor

UCLA David Geffen School of Medicine

e. Peter Doshi, PhD Associate Professor,

Pharmaceutical Health Services Research University of Maryland School of Pharmacy Baltimore, Maryland, U.S.A.

f. Linda Wastila, BSPharm, MSPH, PhD Professor,

Pharmaceutical Health Services Research University of Maryland School of Pharmacy

g. Andrew Bostom, MD, MS Associate Professor of Family Medicine (Research)

The Warren Alpert Medical School of Brown University

h. Erick H. Turner, MD Associate Professor

Oregon Health & Science University

i. Aditi Bhargava, PhD Professor

Emerita Department of ObGyn and Reproductive Sciences University of California San Francisco

j. Joseph A. Ladapo, MD, PhD Associate Professor of Medicine

Division of General Internal Medicine and Health Services Research

David Geffen School of Medicine at UCLA

k. Gabe Vorobiof, MD FACC FASE Director,

Adult Non-Invasive Cardiology Laboratories UCLA Cardiovascular Center Associate Clinical Professor of Medicine David Geffen School of Medicine at UCLA

l. Donald W. Light, PhD Professor of Comparative Health Policy and Psychiatry

Rowan University School of Osteopathic Medicine Glassboro, New Jersey, U.S.A.

m. Allyson M Pollock, MBChB, FRCPH, FRCP (Ed) FRCGP Clinical Professor of Public Health Institute of Health and Society, Newcastle University Newcastle upon Tyne, United Kingdom

n. Anthony J. Brookes, PhD Professor of Genetics

University of Leicester Leicester, United Kingdom

o. László G. Boros, MD Scientific Advisor

SIDMAP, LLC and the Deutenomics Science Institute

p. Angela Spelsberg, MD, SM

Comprehensive Cancer Center Aachen , Germany

q. Christine Stabell Benn, MD, PhD, DMSc Professor of Global Health

University of Southern Denmark Copenhagen, Denmark

r. Peter Aaby, MSc, DMSc Head of Bandim Health Project,

Guinea-Bissau University of Southern Denmark Copenhagen, Denmark

s. Ulrich Keil, MD, PhD, FRCP (London) Professor

Emeritus University of Muenster Muenster, Germany

t. Barbara Mintzes, BA, MSc, PhD Associate Professor,

School of Pharmacy The University of Sydney Sydney, Australia

u. David Healy, MD FRCPsych Professor of Psychiatry

McMaster University Ontario, Canada

v. Tom Jefferson, MD MRCGP FFPHM

Senior Associate Tutor University of Oxford

w. Byram W. Bridle, PhD Associate Professor of Viral Immunology

Department of Pathobiology University of Guelph, Ontario

x. Peter C. Gøtzsche, Professor, DrMedSci, MD, MSc

Director Institute for Scientific Freedom Copenhagen, Denmark

y. Janice E. Graham, PhD, FRSC, FCAHS

Division of Infectious Diseases University research Professor Dalhousie University

z. Justin Lee

Associate Editor Arc Digital

aa. Serena Tinari Co-President,

Re-Check, Investigating and Mapping Health Affairs

bb. Catherine Riva Co-President,

Re-Check, Investigating and Mapping Health Affairs

cc. Dr. Ira Bernstein, MD

Dept. Family and Community Medicine University of Toronto

dd. Dr. Ondrej Halgas, PhD Biomedical Researcher

University of Toronto

ee. Prof. David Menkes Associate Professor

University of Auckland

ff. Dr. Peter Abdelmalak Adjunct Professor

McMaster University


FDA je večkrat obljubila "popolno preglednost" v zvezi s cepivi proti Covid-19, vključno s ponovno potrditvijo "zavezanosti FDA k preglednosti" pri licenciranju Pfizerjevega cepiva Covid-19.


Preglednost v zvezi s tem izdelkom pomeni, če nič drugega, izmenjavo podatkov, na katere se je FDA oprla pri licenciranju tega cepiva. Opredelitev »preglednosti« dobesedno vključuje »dostopnost informacij«. Ali je to preglednost, da FDA zavrne zahtevo, za hitrejšo objavo teh podatkov, skupine visoko pooblaščenih znanstvenikov z večjih univerz po vsej državi?


Če je FDA zavezana preglednosti, zakaj je treba za pravočasno

pridobitev teh podatkov vložiti zvezno tožbo?

Zakaj se FDA tedne po vložitvi zvezne tožbe še vedno ni strinjala s pravočasno objavo teh podatkov?

Zakaj FDA vztrajno odlaša z njegovo izdajo, če celo zvezni zakon navaja, da so po licenci »podatki in informacije v datoteki bioloških izdelkov

[za licencirano cepivo] takoj na voljo za javno razkritje«.


Zahtevamo preglednost, da FDA takoj razkrije podatke, na katere se je oprla pri izdaji licence za cepivo Pfizer. Ne jutri. Danes. Znanstveniki, zdravstveni delavci in vsaka oseba v tej državi,zlasti tisti, ki uvajajo in so odgovorni za uporabo tega izdelka, bi morali imeti dostop do podatkov zdaj.


Dovolj neverjetno je že to, da je zvezna vlada naročila Pfizerjevo cepivo proti Covid-19 za milijone Američanov medtem, ko je Pfizerju dala popolno finančno imuniteto za škodo, ki jo povzroča ta izdelek.


Torej ne morete reči ne, ne morete tožiti za škodo in ne vidite podatkov,

na katerih temelji trditev vlade, da je izdelek varen in učinkovit.


Nekateri bi lahko opisali takšno ravnanje kot avtoritarno. Seveda bi bila takšna trditev verjetno cenzurirana. In cenzura bo seveda pomagala vsem, ki trdijo, da je tak mandat avtoritaren, razumeti, da so zavedeni.


Ne pozabite preučiti pritožbe, vložene v zvezni tožbi proti zelo pregledni FDA. Čez nekaj tednov bi moral imeti novo posodobitev o tem.


Shranite si kompleten dokument v PDF formatu

001-Complaint-101021
.pdf
Download PDF • 1.10MB

DELITE POMEMBNE INFORMACIJE,

TA VOJNA JE V PRVI VRSTI INFORMACIJSKA !!!

260 views0 comments